Sample A shows uniform, well-organized spindle-shaped cells. No abnormalities were detected in either morphological evaluation or genome analysis, and the cells were determined to be suitable for clinical administration.

Sample B appears morphologically similar to normal cells and cannot be distinguished from Sample A by appearance alone. However, genome analysis identified copy errors (mutations) in gene regions that may be associated with tumor development. These cells are therefore excluded from clinical use.

Sample C shows morphological abnormalities, including rounded, uneven shapes with irregular surfaces,rather than the characteristic spindle-shaped structure of healthy stem cells. Such changes may indicate altered cell properties or reduced quality, and these cells are excluded during the culture stage.

As demonstrated, some cells that appear normal may be unsuitable at the genetic level, while others are excluded based on morphological changes. At our clinic, routine morphological monitoring by experienced cell culture specialists is combined with NGS-based genome analysis. This dual approach enables comprehensive risk assessment beyond visual inspection, ensuring that only carefully selected cells deemed suitable for human administration are used.